The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
about
Androgen-modulating agents for spinal bulbar muscular atrophy/Kennedy's diseaseThe dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depressionCurrent medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitationsBest of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FLKorean clinical practice guideline for benign prostatic hyperplasiaUpdate on medical therapy for male LUTSEjaculatory dysfunction in the treatment of lower urinary tract symptomsComparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysisSilodosin for benign prostatic hyperplasia.Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.Preventive effect of tamsulosin on postoperative urinary retention in neurosurgical patients.Inhibition of chronic prostate inflammation by hyaluronic acid through an immortalized human prostate stromal cell line model.Adrenergic α-blockers: an infrequent and overlooked cause of priapism.Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS)Effectiveness of medical and surgical therapies for lower urinary tract symptoms in the community settingNational trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008).Benign Prostatic Hyperplasia Implications for Pharmacologic Treatment and Perioperative Care.Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year rEstrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy.Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasiaThe role of combination medical therapy in benign prostatic hyperplasia.Prospective pharmacologic therapies for the overactive bladderEfficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability.Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.itD-004 ameliorates phenylephrine-induced urodynamic changes and increased prostate and bladder oxidative stress in rats.Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.The Canadian Benign Prostatic Hyperplasia Audit Study (CanBas).BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.Efficient synthesis of chiral beta-arylisopropylamines by using catalytic asymmetric hydrogenation.Emerging drugs for the treatment of benign prostatic obstruction.Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia.The evaluation and treatment of nocturia: a consensus statement.Dutasteride/tamsulosin: in benign prostatic hyperplasia.Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.Androgen receptor roles in the development of benign prostate hyperplasia
P2860
Q24187399-1E717CFD-0FF6-4BC9-B162-FC811B1596EEQ24564068-74152897-CF85-41C8-B994-380F7862C4D2Q24649617-7AE54822-77E0-462D-AF19-D8B934B20272Q24654903-5947BCE5-E89B-4143-BD9D-B14C584C13E7Q26766302-176C2285-7565-48A6-B996-59EC2A3A73F6Q26862710-C14AF8C0-5D35-4FE4-9C18-BDE57CB40021Q28073775-F68059BD-A8DE-4D73-BAC7-DBB4757C4827Q28542960-AF6029EE-8687-410A-9247-2A76796F4D17Q33158241-9DB30E5D-1C32-4078-94F5-4CAD76C19AA4Q33602452-34F71C2E-83F5-4E91-B4D9-9A983CFB0031Q33731400-BD4F0578-2DD2-4ACA-9B4E-01B2ACAF7D43Q33739217-AB1A4C4A-BD3B-4ADD-A353-5D3BEACF8F5FQ33905165-1EEC738E-A615-4572-8289-41B111867898Q34003918-BC5426DA-4DCD-46E6-9D4A-A5BE7BB1994AQ34218260-A31BAC7E-3C1A-49CD-A8C7-5C767F3BDD0EQ34251961-1F4F0510-A856-4A5A-8085-CBCEDD3F6B05Q34338110-C064B202-100F-40B6-8D94-B4F282430508Q34377799-8A8BDDA6-0A15-4F07-B178-5467AC660CABQ34445034-A445CC5E-5694-41F0-8A7D-E1B70A404298Q34637448-5A48FE06-78B7-43A3-9C85-3D5AA579A601Q34643351-043E359C-CCDF-4784-9D20-2A02F082F5A2Q34877827-083A861B-242A-409D-9CFD-92ADBEDB7006Q35076367-03391401-5565-46F6-BC67-3CA50415952CQ35087049-64F765A9-F07E-468D-99DA-5335CB52BBAEQ35093140-584E7B1A-1E02-4DED-AC99-C60E1CC7CFD9Q35328005-EAC542B5-5F57-4FCB-9521-96CBE3B74EC6Q35989759-92974152-5D60-41A1-8226-4CEA9976FFF0Q36379355-F1DB5505-A2FA-4885-B4A5-6BD81F193CEDQ36451183-B8ABE253-7E05-4624-BA5C-5422C8DF02CBQ36737065-B9E3699E-1D88-4A63-B9CA-487B7017DA0BQ36867891-BB056398-269A-49EB-AE83-A4E196C055DEQ37097043-1B05AE32-A516-4D49-9ED2-647003B3D994Q37230480-55D3C93E-BDB9-45BE-B285-59D927EDB860Q37630330-A321C9CC-3142-4E5C-A24F-6DCF7B23BF6FQ37743490-E2546130-4DA5-468F-8253-54C90AAA2AC4Q37790387-27306BE9-F2D7-4470-9237-A5E2A767EB54Q37890031-7540A767-F337-4AEF-8F5B-1AEFAE7D654AQ38006977-B97A65C4-69F5-4863-960E-3CC087465AE7Q38093143-272007D3-C0B4-48C7-AF58-3BF5F05DBCE6Q38097574-D518A9DE-9385-46D1-B232-12BC6FC1E5F9
P2860
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
The effects of dutasteride, ta ...... results from the CombAT study
@ast
The effects of dutasteride, ta ...... results from the CombAT study
@en
The effects of dutasteride, ta ...... results from the CombAT study
@nl
type
label
The effects of dutasteride, ta ...... results from the CombAT study
@ast
The effects of dutasteride, ta ...... results from the CombAT study
@en
The effects of dutasteride, ta ...... results from the CombAT study
@nl
prefLabel
The effects of dutasteride, ta ...... results from the CombAT study
@ast
The effects of dutasteride, ta ...... results from the CombAT study
@en
The effects of dutasteride, ta ...... results from the CombAT study
@nl
P2093
P3181
P1476
The effects of dutasteride, ta ...... results from the CombAT study
@en
P2093
Betsy Morrill
Claus G Roehrborn
Jack Barkin
Kim Major-Walker
Paul Siami
Ronaldo Damião
P304
616-21; discussion 621
P3181
P356
10.1016/J.JURO.2007.09.084
P407
P577
2008-02-01T00:00:00Z